A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Trial details
- Registry ID
- NCT05002127
- Phase
- Phase 2, Phase 3
The FDA approved Trastuzumab (Herceptin) on 25 Sep 1998.
Drug identity checked against registry records
Also recorded as Herceptin; Herceptin®
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1998-09-25Day | Trastuzumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA103792", "applicant_as_listed_by_fda": "GENENTECH", "brand_names": ["HERCEPTIN"], "active_ingredients": ["TRASTUZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19980925", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |